Advertisement
Advertisement
MIST
Milestone Pharmaceuticals Inc. Common Shares
0.79
USDSponsored
-0.07
-7.78%
Sep 24, 15:59 UTC -4
Closed
Pre-Market
0.80
0.00
+0.14%
MIST Earnings Reports
Positive Surprise Ratio
MIST beat 16 of 29 last estimates.
55%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.17M
/-$0.22
Implied change from Q2 26 (Revenue/ EPS)
+108.54%
/+4.76%
Implied change from Q3 25 (Revenue/ EPS)
--
/+83.33%
Milestone Pharmaceuticals Inc. Common Shares earnings per share and revenue
On Aug 12, 2026, MIST reported earnings of -0.21 USD per share (EPS) for Q2 26, missing the estimate of -0.19 USD, resulting in a -5.58% surprise. Revenue reached 559.00 thousand, compared to an expected 833.00 thousand, with a -32.89% difference. The market reacted with a -11.42% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.22 USD, with revenue projected to reach 1.17 million USD, implying an increase of 4.76% EPS, and increase of 108.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Milestone Pharmaceuticals Inc. Common Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Milestone Pharmaceuticals Inc. Common Shares reported EPS of -$0.21, missing estimates by -5.58%, and revenue of $559.00K, -32.89% below expectations.
How did the market react to Milestone Pharmaceuticals Inc. Common Shares's Q2 2026 earnings?
The stock price moved down -11.42%, changed from $1.27 before the earnings release to $1.13 the day after.
When is Milestone Pharmaceuticals Inc. Common Shares expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Milestone Pharmaceuticals Inc. Common Shares's next earnings report?
Based on --
analysts, Milestone Pharmaceuticals Inc. Common Shares is expected to report EPS of -$0.22 and revenue of $1.17M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.